Safety trial adds momentum to India’s growing Ashwagandha supplements market
A Ministry of Ayush-backed trial of 1,200 vaccinated adults found standardised Ashwagandha root extract well tolerated over 24 weeks, with no treatment-related liver or kidney injury. The market is estimated at ₹657 crore in 2025 and projected to reach ₹1,421 crore by 2033.
The development
A Ministry of Ayush-backed trial of 1,200 vaccinated adults found standardised Ashwagandha root extract well tolerated over 24 weeks, with no treatment-related liver or kidney injury. India's supplements market is estimated at ₹657 crore ($68.4 million) in 2025.
The numbers
- ₹657 crore ($68.4 million)
- 2025
- ₹1,421 crore ($148 million)
- 2033
- ₹7,296 crore ($760 million)
Why it matters to operators and investors
The 24-week safety findings may support customer confidence in standardized Ashwagandha products, but keep claims evidence-led and ensure supplier quality and regulatory compliance.
What to watch next
- Further independent studies, especially on efficacy, longer-term use, and populations beyond vaccinated adults.
- Ministry of Ayush or other regulator guidance on Ashwagandha claims, labelling, or quality standards.
- Retail search interest, repeat-purchase rates, and sales mix between standardised and generic products.
- Adverse-event reports, product recalls, or investigations involving liver or kidney injury.
- New market-size estimates and evidence that projected growth is translating into retail sell-through.
The counter-case
The trial supports short-term tolerability for one standardised root extract in a specific group; it does not establish long-term safety, effectiveness, or safety across other products and formulations. A safety finding alone may not materially increase consumer demand or sales.